- Report
- May 2025
- 71 Pages
Global
From €5325EUR$5,850USD£4,473GBP
- Report
- July 2024
- 175 Pages
Global
From €2276EUR$2,500USD£1,912GBP
- Report
- April 2025
- 175 Pages
Global
From €4087EUR$4,490USD£3,433GBP
- Report
- January 2025
- 175 Pages
Global
From €4087EUR$4,490USD£3,433GBP
- Report
- January 2025
- 175 Pages
Global
From €4087EUR$4,490USD£3,433GBP
- Report
- January 2025
- 175 Pages
Global
From €4087EUR$4,490USD£3,433GBP
- Report
- December 2024
- 180 Pages
Global
From €4096EUR$4,500USD£3,441GBP
- Report
- May 2025
- 450 Pages
Global
From €3637EUR$3,995USD£3,055GBP
- Report
- April 2025
- 1500 Pages
Global
From €4547EUR$4,995USD£3,819GBP
- Report
- December 2024
- 581 Pages
Global
From €4506EUR$4,950USD£3,785GBP
- Report
- October 2024
- 195 Pages
Global
From €3227EUR$3,545USD£2,711GBP
€3586EUR$3,939USD£3,012GBP
- Report
- February 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,433GBP
- Report
- January 2025
- 120 Pages
Global
From €5416EUR$5,950USD£4,550GBP
- Report
- January 2025
- 150 Pages
Global
From €5416EUR$5,950USD£4,550GBP
- Report
- May 2025
- 193 Pages
Global
From €5325EUR$5,850USD£4,473GBP
- Report
- May 2025
- 224 Pages
Global
From €5325EUR$5,850USD£4,473GBP
- Report
- January 2025
- 175 Pages
Global
From €4087EUR$4,490USD£3,433GBP
- Report
- February 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,433GBP
- Report
- May 2025
- 284 Pages
Global
From €5325EUR$5,850USD£4,473GBP
- Report
- May 2025
- 273 Pages
Global
From €5325EUR$5,850USD£4,473GBP

Lymphoma is a type of hematological malignancy that originates in the lymphatic system. It is characterized by the uncontrolled growth of lymphocytes, a type of white blood cell. Lymphomas can be either Hodgkin's or non-Hodgkin's, and can be either indolent or aggressive. Treatment options for lymphoma include chemotherapy, radiation therapy, stem cell transplantation, and targeted therapies.
The lymphoma market is a subset of the larger hematology market, which includes treatments for a variety of blood-related diseases. The lymphoma market is driven by the increasing prevalence of the disease, as well as the development of new treatments.
Companies in the lymphoma market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Gilead Sciences, Novartis, and Pfizer. Show Less Read more